This approval marks a significant milestone in OneSource’s ongoing commitment to quality and regulatory compliance
OneSource operates five cGMP facilities and has a strong track record, with 138 successful regulatory and customer audits to date by all major regulatory bodies
The share subscription agreements are being executed at a pre-money equity value of US$ 1.65 billion
Adding 20,000 liters of installed biologics drug substance manufacturing capacity
The company is excited about the strategic progress that the company has made so far and are confident of delivering better business outcomes
The current approval is first of the many fillings made by the company's CDMO partners from the flagship facility in Bangalore
Kauliv provides reusable and disposable pen2 device options to cater to the global market demand.
The integrated capabilities at Unit 2 offer significant operational flexibility, greater efficiency, and varied scope within the same premise
Both manufacturing facilities are based out of Benguluru, India
Stelis's small-scale cGMP manufacturing facility is designed to support smallscale commercial and cGMP clinical trial material generation
Subscribe To Our Newsletter & Stay Updated
